-
Mashup Score: 1
ASCO 2023 ARASENS time to pain progression in patients with high/low prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the ARASENS Trial - Karim Fizazi - 12 month(s) ago
Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the #ARASENS trial. @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/UTSvewcfNi @Bayer https://t.co/KGOarX33NY
-
-
Mashup Score: 0Phase 3 ARASENS Study, The Impact of Disease Burden and Risk on Efficacy and Safety Outcomes - Matthew Smith - 1 year(s) ago
Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Exciting news in #ProstateCancer research! Matthew Smith, MD, PhD @MGHMedicine and @CaPsurvivorship @DanaFarber discuss the positive findings from the #ARASENS study, showing significant improvement in OS for men with #mHSPC. #WatchNow on UroToday > https://t.co/80gCMhoaGS https://t.co/4oeYyNGPcq
-
-
Mashup Score: 3AUA 2023: Rapid, Durable, and Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - 1 year(s) ago
AUA 2023, prostate cancer, prostate specific antigen (PSA), Darolutamide, Docetaxel, androgen deprivation therapy (ADT), ARASENS trial, metastatic hormone-sensitive prostate cancer (mHSPC), docetaxel, PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Rapid, durable, and deep PSA response following the addition of darolutamide to ADT and docetaxel in #ARASENS. Presented by Fred Saad, MD, FRSC @chumontreal. #AUA23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/JwPdYDMCFT https://t.co/KL0uESZZkP
-
-
Mashup Score: 1AUA 2023: Efficacy and Safety of Darolutamide in Combination With ADT Therapy and Docetaxel in the North American Population From ARASENS - 1 year(s) ago
AUA 2023, prostate cancer, ARASENS trial, androgen deprivation therapy (ADT), Darolutamide in Combination With ADT Therapy and Docetaxel in the North American Population, Darolutamide, Docetaxel, castration-resistant prostate cancer (CRPC), metastatic hormone-sensitive prostate cancer (mHSPC).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of darolutamide in combination with ADT therapy and docetaxel in the #NorthAmerican population from #ARASENS. Presented by Neal Shore, MD, FACS @AtlanticUrology. #AUA23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/6wKaS47tk7 @AmerUrological https://t.co/xvSVBmvBsV
-
-
Mashup Score: 1Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the ARASENS Trial - Karim Fizazi - 1 year(s) ago
Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the #ARASENS trial. @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/UTSvewcfNi @Bayer https://t.co/JQlfTdAIpU
-
-
Mashup Score: 0Phase 3 ARASENS Study, The Impact of Disease Burden and Risk on Efficacy and Safety Outcomes - Matthew Smith - 1 year(s) ago
Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Exciting news in #ProstateCancer research! Matthew Smith, MD, PhD @MGHMedicine and @CaPsurvivorship @DanaFarber discuss the positive findings from the #ARASENS study, showing significant improvement in OS for men with #mHSPC. #WatchNow on UroToday > https://t.co/80gCMhoaGS https://t.co/2hu8IJLi30
-
-
Mashup Score: 0
A study published in the Journal of Clinical Oncology examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent study published in the Journal of Clinical Oncology has examined safety and efficacy from the #ARASENS phase 3 trial comparing darolutamide plus ADP with docetaxel for certain subgroups by disease volume and risk. Read more: https://t.co/C13gmJKTO6 https://t.co/74t5lMw9Qt
-
-
Mashup Score: 14Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Observation from #ENZAMET ✅ Adding enzalutamide to TS plus docetaxel had the same treatment effect as adding abiraterone (#PEACE1) to darolutamide (#ARASENS) to TS + docetaxel in pts presenting with synchronous mHSPC https://t.co/zj4jsmIhIf https://t.co/KfWLPR8k7O
-
-
Mashup Score: 0Phase 3 ARASENS Study, The Impact of Disease Burden and Risk on Efficacy and Safety Outcomes - Matthew Smith - 1 year(s) ago
Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Exciting news in #ProstateCancer research! Matthew Smith, MD, PhD @MGHMedicine and @CaPsurvivorship @DanaFarber discuss the positive findings from the #ARASENS study, showing significant improvement in OS for men with #mHSPC. #WatchNow on UroToday > https://t.co/80gCMhoaGS https://t.co/UUJqIDLcco
-
Darolutamide and time to pain progression by disease volume in #ARASENS. Presented by Matthew Smith, MD, PhD @MGHCancerCenter. #ASCO23 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/4q3bivxvWq @ASCO https://t.co/GGXWFfQ0dT